Tomohiro Iwasawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomohiro Iwasawa has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Sato
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
1 shared publication Akihito Kawazoe
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
1 shared publication- Daisuke Ito
Department of Urology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
1 shared publication Eisuke Tomiyama
Department of Urology, Graduate School of Medicine The University of Osaka Osaka Japan
1 shared publication- Fumihiko Urabe
Department of Urology The Jikei University School of Medicine Tokyo Japan
1 shared publication Hiromi Ono
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
1 shared publication
Latest Publications
- 4 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (874)
Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer
Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair–proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells. At progression, LRRC15 + CAFs and APLN + tip cells remained reduced, activated CCR8 + regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1 + lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.
- 4 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (874)
Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer
Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair–proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells. At progression, LRRC15 + CAFs and APLN + tip cells remained reduced, activated CCR8 + regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1 + lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.
- 14 January 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (1) , e70341
Translational Advances in Urothelial Carcinoma: From Bench to Bedside
Urothelial carcinoma (UC), encompassing both bladder cancer and upper tract UC, is a biologically heterogeneous malignancy that has long complicated patient stratification and therapeutic prediction. Recent genomic and transcriptomic analyses, however, have delineated reproducible molecular subtypes across non‐muscle‐invasive and muscle‐invasive disease. These classification frameworks have refined biological understanding and improved both risk stratification and treatment selection. Emerging evidence also indicates that genomic alterations, such as FGFR3 mutations, may confer distinct immunologic phenotypes within specific transcriptomic contexts, thereby challenging prior assumptions. The advent of immune checkpoint inhibitors has transformed UC management, yet variable response rates underscore the complexity of the tumor microenvironment (TME). Single‐cell and spatial analyses have identified immune‐inflamed, ‐desert, and ‐excluded TME subtypes, with cancer‐associated fibroblasts playing a key role in immune exclusion and therapeutic resistance. Liquid biopsy, particularly circulating tumor DNA, has demonstrated utility for real‐time disease monitoring, minimal residual disease detection, and treatment stratification, as highlighted in trials such as IMvigor010 and IMvigor011. Urinary extracellular vesicles also represent promising non‐invasive biomarkers, though further standardization is required. In addition, novel therapeutic strategies—including antibody‐drug conjugates, gene therapies, and sustained‐release delivery systems—are broadening treatment options across disease stages. Collectively, these translational advances mark a paradigm shift toward precision immuno‐oncology in UC. Nonetheless, successful clinical implementation will require prospective validation, optimized analytical platforms, and sustained physician‐scientist engagement to translate these discoveries into improved patient outcomes. This review provides a comprehensive overview of recent progress in UC translational research, with a focus on genomic and transcriptomic insights, the evolving role of immunotherapy, advances in liquid biopsy, and the development of novel therapeutics.
- 14 January 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (1) , e70341
Translational Advances in Urothelial Carcinoma: From Bench to Bedside
Urothelial carcinoma (UC), encompassing both bladder cancer and upper tract UC, is a biologically heterogeneous malignancy that has long complicated patient stratification and therapeutic prediction. Recent genomic and transcriptomic analyses, however, have delineated reproducible molecular subtypes across non‐muscle‐invasive and muscle‐invasive disease. These classification frameworks have refined biological understanding and improved both risk stratification and treatment selection. Emerging evidence also indicates that genomic alterations, such as FGFR3 mutations, may confer distinct immunologic phenotypes within specific transcriptomic contexts, thereby challenging prior assumptions. The advent of immune checkpoint inhibitors has transformed UC management, yet variable response rates underscore the complexity of the tumor microenvironment (TME). Single‐cell and spatial analyses have identified immune‐inflamed, ‐desert, and ‐excluded TME subtypes, with cancer‐associated fibroblasts playing a key role in immune exclusion and therapeutic resistance. Liquid biopsy, particularly circulating tumor DNA, has demonstrated utility for real‐time disease monitoring, minimal residual disease detection, and treatment stratification, as highlighted in trials such as IMvigor010 and IMvigor011. Urinary extracellular vesicles also represent promising non‐invasive biomarkers, though further standardization is required. In addition, novel therapeutic strategies—including antibody‐drug conjugates, gene therapies, and sustained‐release delivery systems—are broadening treatment options across disease stages. Collectively, these translational advances mark a paradigm shift toward precision immuno‐oncology in UC. Nonetheless, successful clinical implementation will require prospective validation, optimized analytical platforms, and sustained physician‐scientist engagement to translate these discoveries into improved patient outcomes. This review provides a comprehensive overview of recent progress in UC translational research, with a focus on genomic and transcriptomic insights, the evolving role of immunotherapy, advances in liquid biopsy, and the development of novel therapeutics.